Recently, Facchinetti et al. reported that NSCLC patients with an ECOG PS of 2 due to comorbidities exhibited a significantly better outcome compared with patients with a similar PS that was secondary to tumor progression when first-line pembrolizumab was administered for PD-L1 expression ≥50% [15]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.